Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF V600X Vemurafenib cholangiocarcinoma sensitive detail...
FGFR2 fusion Infigratinib cholangiocarcinoma sensitive detail...
FGFR2 mutant Infigratinib cholangiocarcinoma sensitive detail...
FGFR2 - ZMYM4 FGFR2 N549H FGFR2 N549K FGFR2 V564F FGFR2 E565A FGFR2 K659M Infigratinib cholangiocarcinoma predicted - resistant detail...
FGFR2 - OPTN FGFR2 N549H FGFR2 V564F FGFR2 E565A FGFR2 L617V FGFR2 K641R Infigratinib cholangiocarcinoma predicted - resistant detail...
FGFR2 - BICC1 FGFR2 V564F Infigratinib cholangiocarcinoma predicted - resistant detail...
FGFR2 fusion FGFR2 V564F Infigratinib cholangiocarcinoma predicted - resistant detail...
IDH1 mutant Ivosidenib cholangiocarcinoma sensitive detail...
FGFR2 fusion Futibatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 rearrange Futibatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 rearrange FGFR2 amp Futibatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 rearrange Pemigatinib cholangiocarcinoma sensitive detail...
FGFR2 - DDX21 Debio 1347 cholangiocarcinoma sensitive detail...
FGFR2 - KIAA1217 Debio 1347 cholangiocarcinoma predicted - sensitive detail...
FGFR2 - ROCK1 Debio 1347 cholangiocarcinoma predicted - sensitive detail...
FGFR2 mutant Erdafitinib cholangiocarcinoma predicted - sensitive detail...
FGFR3 mutant Erdafitinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 fusion Erdafitinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - PPHLN1 Infigratinib cholangiocarcinoma sensitive detail...
FGFR2 - SHTN1 Infigratinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - SHTN1 FGFR2 E565A FGFR2 L617M Infigratinib cholangiocarcinoma predicted - resistant detail...
FGFR2 - SHTN1 FGFR2 E565A Infigratinib cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 FGFR2 L617M Infigratinib cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 AZD4547 cholangiocarcinoma sensitive detail...
FGFR2 - SHTN1 Erdafitinib cholangiocarcinoma sensitive detail...
FGFR2 - SHTN1 Futibatinib cholangiocarcinoma sensitive detail...
FGFR2 - SHTN1 Ponatinib cholangiocarcinoma sensitive detail...
FGFR2 - SHTN1 FGFR2 E565A AZD4547 cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 FGFR2 E565A Erdafitinib cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 FGFR2 E565A Futibatinib cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 Dovitinib cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 FGFR2 E565A Dovitinib cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 FGFR2 L617M AZD4547 cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 FGFR2 L617M Erdafitinib cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 FGFR2 L617M Futibatinib cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 FGFR2 L617M Ponatinib cholangiocarcinoma sensitive detail...
FGFR2 - SHTN1 FGFR2 E565A Ponatinib cholangiocarcinoma sensitive detail...
FGFR2 - TTC28 Infigratinib cholangiocarcinoma sensitive detail...
FGFR2 fusion Pemigatinib cholangiocarcinoma sensitive detail...
FGFR2 - BICC1 Pemigatinib cholangiocarcinoma sensitive detail...
FGFR2 - CLIP1 Pemigatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - CLIP1 FGFR2 N549H Pemigatinib cholangiocarcinoma predicted - resistant detail...
BRAF V600E Vemurafenib cholangiocarcinoma predicted - sensitive detail...
IDH1 R132C Ivosidenib cholangiocarcinoma predicted - sensitive detail...
IDH1 R132S Ivosidenib cholangiocarcinoma predicted - sensitive detail...
IDH1 R132L Ivosidenib cholangiocarcinoma predicted - sensitive detail...
IDH1 R132G Ivosidenib cholangiocarcinoma predicted - sensitive detail...
FGFR3 amp Infigratinib cholangiocarcinoma no benefit detail...
FGFR2 amp Infigratinib cholangiocarcinoma sensitive detail...
FGFR2 - BICC1 Sorafenib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - BICC1 Infigratinib cholangiocarcinoma sensitive detail...
FGFR2 - BICC1 AZD4547 cholangiocarcinoma sensitive detail...
BRAF V600E Dabrafenib + Trametinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 fusion ICP-192 cholangiocarcinoma predicted - sensitive detail...
FGFR2 - KIAA1217 FGFR2 K659M Pemigatinib cholangiocarcinoma predicted - resistant detail...
FGFR2 - AHCYL1 FGFR2 L617V Pemigatinib cholangiocarcinoma predicted - resistant detail...
FGFR2 rearrange Infigratinib cholangiocarcinoma sensitive detail...
FGFR2 - NRBF2 Pemigatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - NRBF2 FGFR2 N549K Pemigatinib cholangiocarcinoma predicted - resistant detail...
FGFR2 - KIAA1217 Pemigatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - CCDC170 Pemigatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - CCDC170 FGFR2 N549K FGFR2 K641R Pemigatinib cholangiocarcinoma predicted - resistant detail...
FGFR2 - AHCYL1 Pemigatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - WDHD1 Pemigatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - PAWR Pemigatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - ATAD2 Pemigatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - ATAD2 FGFR2 N549H Pemigatinib cholangiocarcinoma predicted - resistant detail...
FGFR2 - TRIM8 Pemigatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - TRIM8 FGFR2 E565A FGFR2 L617V FGFR2 K659M Pemigatinib cholangiocarcinoma predicted - resistant detail...
FGFR2 - DDX21 FGFR2 K659M FGFR2 Y779C Debio 1347 cholangiocarcinoma predicted - resistant detail...
FGFR2 - KIAA1217 Infigratinib cholangiocarcinoma sensitive detail...
FGFR2 - KIAA1217 FGFR2 L550F Infigratinib cholangiocarcinoma predicted - resistant detail...
FGFR2 - KIAA1217 FGFR2 N549D FGFR2 N549H FGFR2 N549K FGFR2 V564F FGFR2 V564I FGFR2 V564L FGFR2 E565A FGFR2 L617F FGFR2 L617V FGFR2 K659M FGFR2 Q746L Infigratinib cholangiocarcinoma predicted - resistant detail...
FGFR2 - NRAP Infigratinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - NRAP FGFR2 N549K FGFR2 V564L Infigratinib cholangiocarcinoma predicted - resistant detail...
FGFR2 M537I FGFR2 V564L FGFR2 amp Infigratinib cholangiocarcinoma predicted - resistant detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Suspended USA 0
NCT01438554 Phase I Pazopanib + Trametinib Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma Completed USA 0
NCT01642342 Phase I sEphB4-HSA Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors Active, not recruiting USA 0
NCT01695005 Phase I LY3039478 A Study of LY3039478 in Participants With Advanced Cancer Completed USA 5
NCT01825603 Phase I ADH-1 + Cisplatin + Gemcitabine ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery Completed USA 0
NCT01888302 Phase I Cisplatin + Gemcitabine + Sirolimus Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery Completed USA 0
NCT02024607 Phase Ib/II Capecitabine + Oxaliplatin Bevacizumab + Napabucasin Napabucasin + Regorafenib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Napabucasin Fluorouracil + Irinotecan + Leucovorin A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer Completed USA | CAN 0
NCT02052778 Phase Ib/II Futibatinib A Study of TAS-120 in Patients With Advanced Solid Tumors Completed USA | CAN 12
NCT02053376 Phase II Regorafenib A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy Completed USA 0
NCT02128282 Phase Ib/II Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Silmitasertib Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma Completed USA 2
NCT02150967 Phase II Infigratinib A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma Recruiting USA 10
NCT02187848 Phase Ib/II SAR408701 Evaluation of SAR408701 in Patients With Advanced Solid Tumors Active, not recruiting USA | CAN 3
NCT02232633 Phase II BBI503 A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer Completed CAN 0
NCT02240238 Phase Ib/II Gemcitabine + NC-6004 Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer Completed USA 4
NCT02393248 Phase Ib/II Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Recruiting USA 1
NCT02452970 Phase II RRx-001 Cisplatin + Gemcitabine RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy (EPIC) Terminated USA 0
NCT02479178 Phase II BIND-014 A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (iNSITE2) Terminated USA 1
NCT02508467 Phase I Fisogatinib A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma and Cholangiocarcinoma Active, not recruiting USA 11
NCT02520141 Phase II Ramucirumab Ramucirumab for Advanced Pre-treated Biliary Cancers Active, not recruiting USA 0
NCT02628067 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting USA | CAN 19
NCT02632305 Phase II Cisplatin + Gemcitabine + Nab-paclitaxel A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer (AX-CSARC) Unknown status CAN 0
NCT02638909 Phase II Ceritinib Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies Terminated USA 0
NCT02711553 Phase II Ramucirumab Merestinib Cisplatin + Gemcitabine A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer Active, not recruiting USA 18
NCT02784795 Phase I Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3023414 + LY3039478 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors Completed USA 3
NCT02824042 Phase I Anetumab ravtansine + Itraconazole Anetumab ravtansine Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole Completed USA 5
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting USA 1
NCT02856568 Phase I Cisplatin + Gemcitabine + Ricolinostat Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma Withdrawn USA 0
NCT02924376 Phase II Pemigatinib Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy Completed USA 11
NCT02963831 Phase Ib/II Durvalumab + ONCOS-102 A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Active, not recruiting USA 0
NCT02982720 Phase II Peginterferon alfa-2b + Pembrolizumab Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron Terminated USA 0
NCT02989857 Phase III Ivosidenib Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) Completed USA 5
NCT03093870 Phase II Capecitabine + Varlitinib Capecitabine Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer Completed USA 10
NCT03095781 Phase I Pembrolizumab + XL888 Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer Recruiting USA 0
NCT03102320 Phase I Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) Completed USA | CAN 10
NCT03132792 Phase I AFPc332T AFPc332T in Advanced HCC Recruiting USA 3
NCT03144661 Phase I INCB062079 An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Terminated USA 1
NCT03201458 Phase II Atezolizumab Atezolizumab + Cobimetinib Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT03207347 Phase II Niraparib A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) Suspended USA 0
NCT03212274 Phase II Olaparib Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations Recruiting USA 0
NCT03230318 Phase II Derazantinib Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (FIDES-01) Recruiting USA | CAN 9
NCT03250273 Phase II Entinostat + Nivolumab A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma Active, not recruiting USA 0
NCT03257761 Phase I Durvalumab + Guadecitabine Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Recruiting USA 0
NCT03267940 Phase I Cisplatin + Gemcitabine Atezolizumab + Cisplatin + Gemcitabine + PEGPH20 Cisplatin + Gemcitabine + PEGPH20 Open-Label Study of PEGPH20 With CIS and GEM; PEGPH20 With Atezolizumab, CIS and GEM; and Compared With CIS and GEM Alone in HA-high Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma Terminated USA 2
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Recruiting USA 0
NCT03339843 Phase II Abemaciclib Multiorgan Metabolic Imaging Response Assessment of Abemaciclib (MiMe-A) Recruiting 2
NCT03368963 Phase Ib/II MM-398 + Trifluridine-tipiracil hydrochloride TAS102 in Combination With NAL-IRI in Advanced GI Cancers Recruiting USA 0
NCT03377179 Phase II ABC294640 A Study of ABC294640 in the Treatment of Patients With Advanced Cholangiocarcinoma Recruiting USA 0
NCT03422679 Phase Ib/II CB-103 Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies Recruiting USA 3
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Recruiting USA 0
NCT03656536 Phase III Pemigatinib Cisplatin + Gemcitabine A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302) Recruiting USA | CAN 17
NCT03704480 Phase II Durvalumab + Tremelimumab Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy (IMMUNO-BIL) Recruiting 1
NCT03733990 Phase Ib/II FP-1305 A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) Recruiting USA 5
NCT03773302 Phase III Cisplatin + Gemcitabine Infigratinib Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations Recruiting USA | CAN 12
NCT03797326 Phase II Lenvatinib + Pembrolizumab Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Recruiting USA | CAN 15
NCT03872947 Phase I Pembrolizumab + TRK-950 Carboplatin + Gemcitabine + TRK-950 Imiquimod + TRK-950 Paclitaxel + Ramucirumab + TRK-950 Nivolumab + TRK-950 Cisplatin + Gemcitabine + TRK-950 Fluorouracil + Irinotecan + Leucovorin + TRK-950 A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors Recruiting USA 1
NCT03878095 Phase II Ceralasertib + Olaparib Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors Recruiting USA 0
NCT03943004 Phase I DFP-14927 Trial of DFP-14927 in Advanced Solid Tumors Recruiting USA 0
NCT04003636 Phase III Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) (KEYNOTE-966) Active, not recruiting USA | CAN 22
NCT04003896 Phase II Abemaciclib A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma Who Failed Prior First Line Therapy Active, not recruiting USA 0
NCT04034238 Phase I LMB-100 + Tofacitinib Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors Active, not recruiting USA 0
NCT04057365 Phase II DKN-01 + Nivolumab A Single Arm Phase II Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) Recruiting USA 0
NCT04068194 Phase Ib/II Avelumab Avelumab + MSC2490484A Testing the Combination of New Anti-cancer Drug Nedisertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies Recruiting USA 0
NCT04088188 Phase I Cisplatin + Gemcitabine + Pemigatinib Cisplatin + Gemcitabine + Ivosidenib Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma Recruiting USA 0
NCT04137289 Phase I BI 905711 A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers Recruiting USA 4
NCT04175912 Phase II Carboplatin + MLN4924 + Paclitaxel MLN4924 Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver Suspended USA 0
NCT04233567 Phase II Infigratinib Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations Recruiting USA 0
NCT04294576 Phase I BJ-001 + Pembrolizumab BJ-001 Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors (FIH) Recruiting USA 0
NCT04306367 Phase II Olaparib + Pembrolizumab Study of Pembrolizumab and Olaparib in Bile Duct Cancer Recruiting USA 0
NCT04396821 Phase I TST001 A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT04421820 Phase I BOLD-100 + Fluorouracil + Leucovorin + Oxaliplatin BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours Recruiting CAN 0
NCT04430738 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy for HER2+ Gastrointestinal Cancers Recruiting USA 0
NCT04507503 Expanded access Futibatinib Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements Available USA 0
NCT04521686 Phase I LY3410738 Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 Mutations Recruiting USA 7
NCT04565275 Phase Ib/II ICP-192 A Study of ICP-192 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04641871 Phase I Sym021 + Sym023 Sym021 + Sym022 Sym021 in Combination With Either Sym022 or Sym023 in Patients With Advanced Solid Tumor Malignancies Active, not recruiting USA | CAN 2
NCT04645160 Phase Ib/II Tivozanib Phase I/II Study Evaluating Safety and Efficacy of Tivozanib (AV-951) in Cholangiocarcinoma Not yet recruiting USA 0
NCT04648319 Phase II Nivolumab A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma Recruiting 3
NCT04672434 Phase I Sym021 + Sym024 Sym024 Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Recruiting USA | CAN 0
NCT04676633 Phase I STP705 Open-Label Study for Safety, Tolerability, PK and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy Recruiting USA 0
NCT04677504 Phase II Atezolizumab + Cisplatin + Gemcitabine Atezolizumab + Bevacizumab + Cisplatin + Gemcitabine A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer Active, not recruiting USA | CAN 12
NCT04704154 Phase II Nivolumab + Regorafenib A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors Recruiting USA 7
NCT04717375 Phase Ib/II BND-22 Study of BND-22 in Participants With Advanced Solid Tumors Recruiting USA 1
NCT04781192 Phase Ib/II Durvalumab + Regorafenib The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers Not yet recruiting USA 0
NCT04919642 Phase II TT-00420 Study to Evaluate the Efficacy and Safety of TT-00420 in Cholangiocarcinoma Not yet recruiting USA 0
NCT04973163 Phase I BI 1823911 + Midazolam BI 1701963 + BI 1823911 A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation Recruiting USA 1
NCT05001282 Phase Ib/II ELU001 A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRalpha) Recruiting USA 0
NCT05007106 Phase II MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) Recruiting USA 6